Evidence map›Paper›PMID 34029345›Full record

Trial reportPloS one2021

Factors indicating intention to vaccinate with a COVID-19 vaccine among older U.S. adults.

Janeta Nikolovski, Martin Koldijk, Gerrit Jan Weverling, John Spertus, Mintu Turakhia, Leslie Saxon, Mike Gibson, John Whang, Troy Sarich, Robert Zambon and 6 more

Registry-linked trialOpen access · goldAbstract readClinical Trial
In one paragraph

Trial report in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04276441 (HEARTLINE - A Heart Health Study Using Digital Technology to Investigate if Early AF Diagnosis Reduces the Risk of Thromboembolic Events Like Stroke IN the Real-world Environment), which is not on this map. Cited by 58 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 4 pooled it
9.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04276441 completednot on this map

HEARTLINE - A Heart Health Study Using Digital Technology to Investigate if Early AF Diagnosis Reduces the Risk of Thromboembolic Events Like Stroke IN the Real-world Environment

TypeobservationalSponsorJanssen Scientific Affairs, LLCRan2020 to 2025Enrolled34,244ConditionsAtrial FibrillationArmsHeart healthy Engagement Program with the Apple Watch Series 5 or later, Anti-Coagulation Adherence Module with the Apple Watch Series 5 or later
3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 4 syntheses or guidelines pooled it, 82 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 1 country.

Janeta NikolovskiJanssen Pharmaceutical Companies of Johnson & Johnson, Titusville, NJ, United States of America.ORCID 0000-0001-7271-9637
Martin KoldijkJanssen Pharmaceutical Companies of Johnson & Johnson, Titusville, NJ, United States of America.
Gerrit Jan WeverlingJanssen Pharmaceutical Companies of Johnson & Johnson, Titusville, NJ, United States of America.
John SpertusDepartment of Internal Medicine, University of Missouri-Kansas City, Kansas City, MO, United States of America.
Mintu TurakhiaDepartment of Medicine, Stanford University, Palo Alto, CA, United States of America.
Leslie SaxonDepartment of Medicine, University of Southern California, Los Angeles, CA, United States of America.
Mike GibsonDepartment of Medicine, Harvard, Boston, MA, United States of America.ORCID 0000-0002-4857-9125
John WhangJanssen Pharmaceutical Companies of Johnson & Johnson, Titusville, NJ, United States of America.
Troy SarichJanssen Pharmaceutical Companies of Johnson & Johnson, Titusville, NJ, United States of America.
Robert ZambonJanssen Pharmaceutical Companies of Johnson & Johnson, Titusville, NJ, United States of America.
Nnamdi EzeanochieJohnson & Johnson, New Brunswick, NJ, United States of America.
Jennifer TurgissJohnson & Johnson, New Brunswick, NJ, United States of America.
Robyn JonesJohnson & Johnson, New Brunswick, NJ, United States of America.
Jeff StoddardJanssen Pharmaceutical Companies of Johnson & Johnson, Titusville, NJ, United States of America.
Paul BurtonJanssen Pharmaceutical Companies of Johnson & Johnson, Titusville, NJ, United States of America.ORCID 0000-0002-7955-6225
Ann Marie NavarDepartment of Medicine, UT Southwestern Medical Center, Dallas, TX, United States of America.
Johnson & Johnson (United States) · USHarvard University · USSouthwestern Medical Center · USStanford University · USUniversity of Missouri–Kansas City · USUniversity of Southern California · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe success of vaccination efforts to curb the COVID-19 pandemic will require broad public uptake of immunization and highlights the importance of understanding factors associated with willingness to receive a vaccine.

methodsU.S. adults aged 65 and older enrolled in the HeartlineTM clinical study were invited to complete a COVID-19 vaccine assessment through the HeartlineTM mobile application between November 6-20, 2020. Factors associated with willingness to receive a COVID-19 vaccine were evaluated using an ordered logistic regression as well as a Random Forest classification algorithm.

resultsAmong 9,106 study participants, 81.3% (n = 7402) responded and had available demographic data. The majority (91.3%) reported a willingness to be vaccinated. Factors most strongly associated with vaccine willingness were beliefs about the safety and efficacy of COVID-19 vaccines and vaccines in general. Women and Black or African American respondents reported lower willingness to vaccinate. Among those less willing to get vaccinated, 66.2% said that they would talk with their health provider before making a decision. During the study, positive results from the first COVID-19 vaccine outcome study were released; vaccine willingness increased after this report.

conclusionsEven among older adults at high-risk for COVID-19 complications who are participating in a longitudinal clinical study, 1 in 11 reported lack of willingness to receive COVID-19 vaccine in November 2020. Variability in vaccine willingness by gender, race, education, and income suggests the potential for uneven vaccine uptake. Education by health providers directed toward assuaging concerns about vaccine safety and efficacy can help improve vaccine acceptance among those less willing.

trial registrationClinicaltrials.gov NCT04276441.

Indexed as

AgedAged, 80 and overCOVID-19FemaleHealth Knowledge, Attitudes, PracticeHumansMaleMass VaccinationPatient ParticipationSocioeconomic FactorsUnited StatesVaccination Refusal

Identifiers

PMID34029345
PMCPMC8143399
OpenAlexW3165415218

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.